These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34254203)

  • 21. Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
    Vastesaeger N; Kutzbach AG; Amital H; Pavelka K; Lazaro MA; Moots RJ; Wollenhaupt J; Zerbini CA; Louw I; Combe B; Beaulieu A; Schulze-Koops H; Dasgupta B; Fu B; Huyck S; Weng HH; Govoni M; Durez P
    Rheumatology (Oxford); 2016 Aug; 55(8):1466-76. PubMed ID: 27114562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-α inhibitor in Crohn disease patients.
    Shi X; Yang W; Wang N; Zhu J
    Medicine (Baltimore); 2019 Aug; 98(33):e16622. PubMed ID: 31415355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years.
    Andersson ML; Svensson B; Bergman S
    J Rheumatol; 2013 Dec; 40(12):1977-85. PubMed ID: 24187108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
    Kaneko Y; Kondo H; Takeuchi T
    J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of patients with rheumatoid arthritis in clinical remission: the many aspects of DAS28 remission.
    Son KM; Song SH; Lim SK; Seo YI; Kim HA
    Clin Exp Rheumatol; 2012; 30(6):947-50. PubMed ID: 22935437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
    Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
    Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
    Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
    Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis.
    Gerber LH; Furst G; Yarboro C; el-Gabalawy H
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S65-70. PubMed ID: 14969053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
    Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
    Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes.
    Mou X; Jin Y; Jin D; Guan J; Zhang Q
    J Clin Lab Anal; 2022 Aug; 36(8):e24594. PubMed ID: 35792020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors.
    Wang F; Liu G; Xiang L; Yuan J; Tao Y; Zhang L; Zhang A; Chang X
    J Clin Lab Anal; 2022 Jun; 36(6):e24449. PubMed ID: 35500150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.